Christopher R. Cahoon, PharmD defines the importance of optimizing bone health in patients with bone metastases and lytic lesions, describes preferred bone-targeted therapy for patients with malignancy-associated bone disease and discusses the safety limitations associated with bisphosphonates and RANKL inhibitors.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
